Zemuron
Zemuron - General Information
Zemuron competes with acetylcholine (ACh) molecules and binds to muscarinic acetylcholine receptors on the post-synaptic membrane of the motor endplate. It is indicated for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Pharmacology of Zemuron
Zemuron is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration
Zemuron for patients
Zemuron Interactions
Drug Interactions: The use of ZEMURON® (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied.
If ZEMURON® is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. The median duration of action of ZEMURON® 0.6 mg/kg administered after a 1 mg/kg dose of succinylcholine when T 1 returned to 75% of control was 36 minutes (range 14-57, n=12) vs. 28 minutes (17-51, n=12) without succinylcholine.
There are no controlled studies documenting the use of ZEMURON® before or after other nondepolarizing muscle relaxants. Interactions have been observed when other nondepolarizing muscle relaxants have been administered in succession.
Drug/Laboratory Test Interactions: None known.
Zemuron Contraindications
ZEMURON® (rocuronium bromide) Injection is contraindicated in patients known to have hypersensitivity to rocuronium bromide.
Additional information about Zemuron
Zemuron Indication: For inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Mechanism Of Action: Zemuron competes with acetylcholine (ACh) molecules and binds to muscarinic acetylcholine receptors on the post-synaptic membrane of the motor endplate. It blocks the action of ACh and prevents activation of the muscle contraction process. It can also act on nicotinic presynaptic acetylcholine receptors which inhibits the release of ACh.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Rocuronium
Synonyms: Not Available
Drug Category: Neuromuscular Nondepolarizing Agents; Skeletal Muscle Relaxants
Drug Type: Small Molecule; Approved
Other Brand Names containing Rocuronium: Rocuronium bromide; Zemuron;
Absorption: Not Available
Toxicity (Overdose): No cases of significant accidental or intentional overdose have been reported. Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.
Protein Binding: Approximately 30% bound to human plasma proteins.
Biotransformation: Not Available
Half Life: The rapid distribution half-life is 1-2 minutes and the slower distribution half-life is 14-18 minutes. Renal impairment has no net effect on half-life, however, half-life is almost doubled in patients with impaired liver function.
Dosage Forms of Zemuron: Liquid Intravenous
Chemical IUPAC Name: [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
Chemical Formula: C32H53N2O4+
Rocuronium on Wikipedia: https://en.wikipedia.org/wiki/Rocuronium
Organisms Affected: Humans and other mammals
